Mutations in the BRCA1 and BRCA2 genes elevate a person’s lifetime risk of getting aggressive, hereditary malignancies such as triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSOC). If a patient has these inherited mutations, it’s possible that her sisters, daughters and other relatives might have the same risk-increasing mutations.
This moon shot offers personalized genetic screening and counseling to TNBC and HGSOC patients to see if they have mutations in their BRCA genes and also offers the same to the family members of those who test positive. Learn more about the moon shot’s Research, Education and Awareness of Cancer family History (REACH) program that was first launched in 2014. The first phase of the program has been so informative to clinical successes that leaders of the moon shot are exploring ways to extend personalized genetic screening and counseling to breast cancer patients and their family members across the United States.
Finding the right target
A flood of new knowledge and technology makes now the time to fast-track the cancer fight and make a giant leap for patients. We’re merging today’s high potential for achievement with our unique knowledge and expertise, derived from decades of leadership in the cancer field.
Most successful treatments for breast cancer take aim at specific proteins expressed by individual tumors: estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2). But TNBC doesn’t express any of these biomarkers, so there’s no current option for targeted therapy. This limits treatment mainly to surgery and chemotherapy, which are less effective against TNBC. Even if caught early, TNBC has an overall five-year survival of 60% compared to 80% for other types. To improve patient outcomes, we’re researching novel genetic markers to identify new plans of attack.
Gifts to this research program will help increase our biological understanding of TNBC and allow us to identify and develop new targeted therapies, plus strategies for prevention and early detection. Our goal is to offer the most personalized course of therapy possible, optimized to match — and defeat — each patient’s tumor at the molecular level.